Amgen Stock Hits 12-Month High After Q2 Beat and Raised Guidance

Amgen stock is trading near its 12-month high after the company delivered strong second-quarter results, beating earnings and revenue expectations. As of August 24, 2026, the shares opened at $443.84 and touched an intraday high of $445.87.

The robust Q2 performance was driven by growth in established therapies, as well as newer launches across key disease areas, including osteoporosis treatment Evenity and cardiovascular drug Repatha. Revenue increased 9.5% compared to the same period a year earlier, while earnings per share rose from $6.02 to $6.29.

Amgen's full-year non-GAAP EPS guidance was also raised to a range of $22.30 to $23.50 per share, which aligns with analysts' forecasts and represents a meaningful step up from prior-year earnings levels.